Sequential Myeloablative Autologous Stem Cell Transplantation Followed by Allogeneic Non-Myeloablative Stem Cell Transplantation for Patients With Poor Risk Lymphomas
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Busulfan; Cyclophosphamide; Etoposide; Filgrastim; Fludarabine; Methotrexate; Sirolimus; Tacrolimus
- Indications Diffuse large B cell lymphoma; Graft-versus-host disease; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; T-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 09 Mar 2017 Biomarkers information updated
- 29 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 May 2013 Planned end date changed from 1 Aug 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov.